New York, March 1, 2026, 15:18 (EST) — Market closed.
AbbVie Inc. shares closed up 3.3% at $232.08 on Friday, ending the week on a firm note as U.S. markets remained shut on Sunday. The stock was last quoted at $231.13 in after-hours trading on Friday. 1
The gain bucked a weak session for the broader market, with the S&P 500 down 0.43% and the Dow off 1.05% on the day. AbbVie outpaced other large drugmakers, and trading volume ran above its recent average, a sign buyers stepped in after a three-day slide. 2
With the next session still a day away, traders are lining up the near-term catalysts: insider activity disclosed after the close, a scheduled management appearance, and a bond sale due to settle this week. None of it changes the long debate on AbbVie’s growth engine, but it can move the tape.
A Form 4 filing showed EVP, general counsel and secretary Perry C. Siatis exercised options and sold 22,381 shares at $230 on Feb. 25, leaving him with 38,137 shares directly owned. Form 4 filings are required disclosures of insider transactions with the U.S. Securities and Exchange Commission. 3
Investors have also been digesting AbbVie’s planned senior notes sale, a debt deal the company laid out in a recent 8-K. AbbVie said the offering is expected to generate about $7.95 billion in net proceeds and close on March 4; it plans to use the money to repay borrowings under a short-dated term loan and for general corporate purposes, including other debt repayment.
Next up is Tuesday. AbbVie said management will appear at TD Cowen’s annual health care conference on March 3, with a fireside chat slated for 10:10 a.m. Central Time and a webcast available through its investor site. 4
The bigger question still sits with the products. AbbVie has told investors it expects 2026 adjusted profit of $14.37 to $14.57 per share and sees Rinvoq and Skyrizi generating about $31.6 billion in combined 2026 sales; CFO Scott Reents flagged “low-single-digit pricing headwinds.” William Blair analyst Matt Phipps said investors have “concerns about growing competition” in immunology, including from Johnson & Johnson’s Tremfya. 5
That competition risk cuts both ways for the stock. A clean set of comments on demand and pricing can extend Friday’s move, but any hint of share loss, tougher rebates, or slower uptake for newer therapies tends to hit this name fast.
For Monday’s open, investors will be watching whether AbbVie can hold onto the late-week pop in a market that has been quick to rotate in and out of big pharma. The next hard checkpoints are Tuesday’s TD Cowen appearance and Wednesday’s expected settlement of the notes sale.
